Iván R. González: Meta – analysis on the first-line treatment of NSCLC with EGFR mutation and brain metastases

Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared on X:

“An excellent meta-analysis on the first-line treatment of NSCLC with EGFR mutation and brain metastases:

Key Findings

• Systematic review of 24 RCTs (n=2682) comparing EGFR TKIs and combination therapies.
• Bevacizumab + 1G TKI improved overall survival (HR: 0.704; 95% CI: 0.433-0.973).
• Chemotherapy + 1G TKI also increased OS (HR: 0.682; 95% CI: 0.464-0.899).
• 3G TKIs showed no significant benefit in OS vs 1G TKIs (HR: 0.855; 95% CI: 0.511-1.198).
• 3G TKIs + chemotherapy showed the greatest improvement in OS (HR: 1.69) and PFS (HR: 2.13).
• Intracranial control was better with 1G TKI and bevacizumab.

The combination of 3G TKIs and chemotherapy appears to be the most effective strategy. More comparative studies are needed.”

Source: Iván R. González/X

First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

Authors: Jietao Ma, Xiaoxue Pang, Shuling Zhang, Letian Huang, Li Sun and Chengbo Han